QNRX
Quoin Pharmaceuticals, Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Quoin Pharmaceuticals, Ltd.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
No changes.
No changes.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. It offers QRX003, a topical lotion to treat Netherton Syndrome; QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company was incorporated in 2018 and is based in Ashburn, Virginia.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. It offers QRX003, a topical lotion to treat Netherton Syndrome; QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company was incorporated in 2018 and is based in Ashburn, Virginia.
No thesis.
No peers for Quoin Pharmaceuticals, Ltd. yet.
No peers for Quoin Pharmaceuticals, Ltd. yet.
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
—
Largest filed tie
—
Quoin Pharmaceuticals, Ltd.
3.94
−0.21 · −4.95%
+80.14%
shares held · 10 largest managers
| Manager | Value | % base | |
|---|---|---|---|
| Stonepine | $3.7M | 41.04% | +1332.00% |
| Dauntless Investment | $1.0M | 11.52% | +9.36% |
| Ikarian Capital | $1.0M | 11.34% | 0.00% |
| Millennium | $543,643 | 6.02% | +47.31% |
| SummitTX Capital | $485,452 | 5.38% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Stonepine | $3.7M | 41.04% | +1332.00% |
| Dauntless Investment | $1.0M | 11.52% | +9.36% |
| Ikarian Capital | $1.0M | 11.34% | 0.00% |
| Millennium | $543,643 | 6.02% | +47.31% |
| SummitTX Capital | $485,452 | 5.38% | 0.00% |
—
—
Expected move
No implied move.